TMCnet News
XOMA Announces Natasha Hernday Joins its Board of DirectorsEMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has joined the Company’s Board of Directors. Ms. Hernday has 20 years of experience in corporate development and corporate strategy work and an extensive record of asset licensing, partnerships, and acquisition transactions. “We graciously welcome Natasha to the XOMA Board of Directors. Natasha has had an exceptional career in corporate development, both at Seattle Genetics and at Amgen. Her expertise in sourcing, evaluating and negotiating licensing deals, acquisitions, and partnerships are complementary to our royalty aggregator business model and are expected to benefit XOMA and our stakeholders as we continue to build our royalty portfolio,” said Jim Neal, Chief Executive Officer at XOMA. “XOMA’s royalty aggregator business model focuses heavily on business development activities within the biotech industry to benefit patients and shareholders. These align with my personal passions and professional expertise. I look forward to joining the XOMA Board to help the Company further its mission of advancing breakthroughs in human health through its royalty aggregation strategy,” commented Ms. Hernday. Ms. Hernday joined Seattle Genetics in 2011 and is responsible for the Company’s in-licensing, collaboration and acquisition transactions, in addition to serving as a member of the Executive Committee. Notably, her team led the 2018 acquisition of Cascadian Therapeutics, which included TUKYSA™ (tucatinib), which received marketing approval in the U.S. and Switzerland in 2020. Prior to joining Seattle Genetics, she spent 16 years at Amgen, initially in research, then transitioning into project management and ultimately corporate development. Ms. Hernday has served on the Boad at PDL BioPharma, Inc., since June 2019. Ms. Hernday received her Masters in Business and Administration from Pepperdine University and her Bachelors degree in Microbiology with an emphasis on Medical Microbiology from University of California Santa Barbara. About XOMA Corporation Forward-Looking Statements/Explanatory Notes EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. Investor contact: Media contact: |